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OBJECTIVE: Bone metastasis is frequently associated with nasopharyngeal carcinoma. The diagnosis and follow-
up of bone metastatic patients usually relies on skeletal X-ray and bone scintigraphy, which are time-consuming
and costly. This study aimed to evaluate whether serum alkaline phosphatase offers clinical value in predicting
the clinical response and survival outcome for skeletal metastatic nasopharyngeal carcinoma.
METHODS: Serum alkaline phosphatase was measured at baseline and then before each cycle of treatment in
416 nasopharyngeal carcinoma patients with bone metastasis. The correlations between the pre-treatment and
post-treatment alkaline phosphatase levels and the treatment efficacy were analyzed using the chi-square test.
Survival was analyzed using the Kaplan–Meier method and then compared using the log-rank test.
RESULTS: Patients with elevated pre-treatment alkaline phosphatase (4110 IU/L) had significantly worse
progression-free survival (Po0.001) and overall survival (Po0.001) than those with a normal level of this marker
(r110 IU/L). Patients with elevated post-treatment alkaline phosphatase had worse progression-free survival
(Po0.001) and overall survival (Po0.001) compared with those with a normal level. Patients with normal pre-
treatment and post-treatment alkaline phosphatase showed the most favorable prognosis. The Cox multivariate
analysis revealed that only the pre-treatment and post-treatment alkaline phosphatase levels were independent
prognostic factors for progression-free survival (HR=1.656, Po0.001; HR=2.226, Po0.001) and for overall
survival (HR=1.794, Po0.001; HR=2.657, Po0.001).
CONCLUSIONS: Serum alkaline phosphatase appears to be a significant independent prognostic index in
patients with skeletal metastatic nasopharyngeal carcinoma, which could reflect the short-term treatment
response of palliative chemotherapy and the long-term survival outcomes.
KEYWORDS: Nasopharyngeal carcinoma; Palliative chemotherapy; Serum alkaline phosphatase; Skeletal
metastasis.
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Nasopharyngeal carcinoma (NPC) is a leading form of
cancer in several well-defined populations, such as the
natives of southern China, Southeast Asia, the Arctic, the
Middle East, and North Africa (1,2). With advances in
radiotherapy techniques, the regional control rate of NPC has
increased remarkably (3). In recent years, the combination of
targeted medicine with intensity-modulated radiotherapy has
also brought promising results for locoregionally advanced
NPC (4,5). The majority of deaths occur not because of the
tumor in the primary site but rather because of distant
metastasis. Different reports have shown that approximately
17% to 54% of patients with NPC failed treatments due to
distant metastases and that approximately one-third of
patients presented disseminated disease at the primary
diagnosis (6). Bone is one of the preferred target sites for
cancer metastasis. NPC has a propensity to spread to bone,
and most of the patients who present with bone metastasis
have an increased risk of skeletal-related events (SREs),
including receiving radiotherapy for bone pain, pathological
fracture, spinal cord compression and hypercalcemia, all of
which result in reduced quality of life and an increased risk
of death (7).
Once bony metastasis has been diagnosed, the current
standard treatment modality for these patients essentiallyDOI: 10.6061/clinics/2015(04)08
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involves cisplatin-based palliative chemotherapy with or
without local radiation therapy according to the symptoms
of bone pain (8). Determining the early response to treatment
is essential to the subsequent management in disseminated
NPC patients. In the past, the tumor evaluation criteria
developed by the WHO defined bone tumor response by the
change of lesion size in skeletal scintigraphy and plain
radiography. However, because the change in osteodestruc-
tive lesion size is always slow, this method is not useful
in clinical practice (9). Currently, the most scientific and
widely used tumor response criteria in the clinical setting are
the Response Evaluation Criteria in Solid Tumors (RECIST),
but in this system, bone metastasis is classified as ‘non-
measurable' and a ‘non-target lesion' (10). As a result, a
readily available biomarker that may enhance the ability to
predict the short-term treatment response and long-term
survival outcome of NPC patients with bone metastasis is
urgently needed.
Serum alkaline phosphatase (S-ALP) has been extensively
used to screen patients for bone metastasis because it is a
simple and inexpensive routine hospital test that is easily
available and yields quick results. The prognostic role of
S-ALP has been explored in various types of malignancies
with bony metastatic disease. Both the baseline S-ALP and
changes in S-ALP have been reported as prognostic factors
for treatment effect and survival such as in bony metastatic
prostate cancer (11), bony metastatic breast cancer (12), and
clear cell chondrosarcoma of the bone (13). In our previous
study (14), we showed that elevated pretreatment S-ALP was
an independently negative prognosticator for disseminated
NPC. However, to the best of our knowledge, there is no
previous research that has explored the clinical application of
S-ALP changes in patients with skeletal metastatic NPC
receiving palliative chemotherapy.
The aim of this retrospective study was to investigate the
prognostic value of S-ALP as a tumor marker in patients
with bony metastatic NPC treated with systemic chemother-
apy. Pre-treatment and post-treatment S-ALP levels were
measured. The correlations of the S-ALP levels to the
treatment response evaluation and survival outcome were
analyzed.
Patients and methods
Inclusion criteria and enrollment. The charts of 1,380 patients
with metastatic NPC admitted to Zhejiang Cancer Hospital
between January 2000 and December 2011 were reviewed. The
following inclusion criteria were applied: (i) patients with
histological confirmation of NPC; (ii) patients with radiological
confirmation of bone metastatic lesion(s); (iii) patients with a
good performance status (Karnofsky Performance ScoresZ80);
(iv) patients with the appropriate renal, cardiac and liver
function to tolerate chemotherapy; (v) patients with
complete pre-treatment and post-treatment S-ALP records;
and (vi) patients with complete follow-up data. The
following exclusion criteria were applied: (i) patients with
other types of malignancy; (ii) patients agedo18 years; and
(iii) patients who were pregnant at the time of diagnosis.
Finally, we were able to retrieve the data for 416 patients.
Definition. Metastasis at the time of presentation was defined
as patients who presented with distant metastasis when first
diagnosed with NPC. This feature was analyzed as a separate
category from the patients who presented with localized
disease but then developed metastases at a later date. The
SREs were classified as fractures, spinal cord compression,
radiation to bone, surgery on bone and hypercalcemia.
Progression-free survival (PFS) was defined as the time from
the first diagnosis of metastasis to disease progression (newly
occurring metastatic lesion, recurrence or the expansion of the
primary lesion). Overall survival (OS) was defined as the time
from the first diagnosis of metastasis to the time of death.
Patients whose deaths were not caused by cancer progression
were excluded from the study.
S-ALP was estimated using the optimized standard method
recommended by the German Society of Clinical Chemistry
(15). S-ALP levels lower than 110 IU/L were considered normal
because this value corresponds to the extreme range that can be
found in a normal population using the method described
above. S-ALP 4110 IU/L was considered a sign of pathology.
Evaluation protocol. The short-term treatment efficacy in
patients with measurable lesions was evaluated by measur-
ing the response every 2 treatment cycles during treatment
and then every 3 months until death. The response of the
tumor to therapy was evaluated based on computed
tomography (CT) or magnetic resonance imaging (MRI)
scans. The short-term efficacy, based on the RECIST, was
assessed as CR, PR, SD and PD; CR and PR were regarded as
responses to treatment. The long-term efficacy was evaluated
according to the PFS and OS.
Statistical analysis. Statistical analysis was performed using
the SPSS 17.0 package. Correlations between the S-ALP
levels and several variables were assessed using the product
moment correlation coefficient (r). The relationship between
short-term treatment efficacy and S-ALP was analyzed
using the chi-square test. Survival was analyzed using
the Kaplan–Meier method and then compared using the
log-rank test. Univariate and multivariate analyses were
performed using the Cox proportion hazards model.
P-values for differences between proportions were calcu-
lated using Fisher's exact test (two-tailed). Statistical
significance was defined as Po0.05.
’ RESULTS
Descriptive characteristics
These features are shown in Table 1. All patients were of
Chinese ethnicity with a male predominance (85.1%). The
mean age at diagnosis of metastatic NPC was 44.9 years
(ranging from 18 to 70 years). Approximately one-third of
the patients had distant metastasis at presentation, and
63.7% of the patients had vertebral metastases. Two hundred
and thirty-one (55.5%) patients had more than one metastatic
site, and more than half of the patients had visceral
metastasis (lung or liver). Among the 416 patients, the
incidence rate of SREs was 39.9%.
Two hundred and thirteen (50.0%) patients showed an
increased pretreatment S-ALP. Sex and age, as well as
metastases at the time of presentation, did not influence the
pretreatment S-ALP levels. The presence of an elevated
S-ALP level (4110 IU/L) was significantly correlated with
the involvement of more than one metastatic site (P = 0.001,
r = 0.167) and specific liver metastasis (Po0.001, r = 0.218), as
well as the presence of SREs (P = 0.016, r = 0.118). The levels
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of S-ALP did not correlate with the presence of lung effusion
and vertebral effusion.
Treatment
An overwhelming majority (70.9%) of the patients were
treated with cisplatin-based doublets. The most frequently
used regimens included cisplatin (25 mg/m2 intravenously
on days 1-3 every 21 days) plus 5-fluorouracil (600 mg/m2
intravenously on days 1-5 every 21 days) and paclitaxel
(175 mg/m2 intravenously over 3 hours on day 1 every 21
days) plus cisplatin (25 mg/m2 intravenously on days 1-3
every 21 cycles). One hundred and one (29.1%) patients received
a triple-drug combination chemotherapy. The most frequently
used regimen was paclitaxel (150 mg/m2 intravenously over
3 hours on day 1 every 21 days) plus cisplatin (25 mg/m2
intravenously on days 1-3 every 21 cycles) plus 5-fluorouracil
(500 mg/m2 intravenously on days 1-5 every 21 days).
Correlation between S-ALP and treatment response
For the 217 patients who had measurable lesions (with
lung or liver metastasis), the overall clinical response rate
was 59.0% (CR in 6 patients and PR in 122 patients).
The difference between the response (CR and PR) rate of
patients with normal baseline S-ALP levels (CR= 5 and
PR= 55) and those with elevated baseline S-ALP levels
(CR=1 and PR=67) was not significant (P= 0.217) (Figure 1A).
Among the 121 patients with elevated pre-treatment
S-ALP levels, a drop in the post-treatment S-ALP to a
normal level at any time during the treatment was noted in
72 (59.5%) patients. All 6 patients who achieved CR showed
a normal post-treatment S-ALP. Thirty-nine of the PR and 14
of the SD patients showed a sharp drop in S-ALP from an
elevated level to a normal level. The response rate was
significantly higher in patients with a normal post-treatment
S-ALP level (CR= 6 and PR= 94) compared with those with
sustained high post-treatment S-ALP levels (CR= 0 and
PR= 28) (Po0.001) (Figure 1B).
Correlation between S-ALP and survival outcome
The mean PFS and OS for the total 416 patients were 8.3
(0.5-75.5) and 23.3 (2.0-106.0) months, respectively. The mean
PFS and OS in patients with a normal baseline S-ALP level
were significantly longer than in those with elevated S-ALP
levels (the mean PFS was 10.3 vs. 6.1 months, Po0.001; the
mean OS was 28.8 vs. 17.6 months, Po0.001) (Figure 2A and
2B). The mean PFS and OS in patients with normal post-
treatment S-ALP levels were significantly longer than those
with elevated S-ALP levels (the mean PFS was 9.7 vs. 4.8
months, Po0.001; the mean OS was 27.5 vs. 13.4 months,
Po0.001) (Figure 2C and 2D).
The 416 patients were divided into four subgroups
according to their pre-treatment S-ALP level and post-
treatment S-ALP level: 1) elevated pre-treatment S-ALP
and elevated post-treatment S-ALP (83 patients); 2) elevated
pre-treatment S-ALP and normal post-treatment S-ALP
(120 patients); 3) normal pre-treatment S-ALP and elevated
post-treatment S-ALP (39 patients); 4) normal pre-treatment
S-ALP and normal post-treatment S-ALP (174 patients).
The mean PFS for these four subgroups was 4.4, 7.3, 5.7 and
11.3 months, respectively (Po0.001). The mean OS was 11.5,
21.8, 17.5 and 31.4 months, respectively (Po0.001) (Fig. 2E
and Fig. 2F).
Prognostic factors for survival outcome
Factors that were incorporated into the analysis included
patient factors (age group, gender), disease factors (metastasis
at presentation, visceral involvement, vertebral involvement,
number of involved sites, pre-treatment and post-treatment
S-ALP levels, presence of SREs) and treatment factor (number
of drugs for chemotherapy).
The Cox multivariate analysis identified that only the
pre-treatment S-ALP level and post-treatment S-ALP level
were independent prognostic factors for PFS (HR=1.656,
Po0.001; HR=2.226, Po0.001) and for OS (HR=1.794,
Po0.001; HR=2.657, Po0.001) (Tables 2 and 3).
Table 1 - Increased S-ALP according to several variables in the 416 patients.
No. of cases Elevated S-ALP % r-value p-value
Sex
Male 354 171 48.3 0.024 0.632
Female 62 32 51.6
Age
o45 years 211 109 51.7 0.058 0.237
Z45 years 205 94 45.9
Metastasis at presentation
Present 148 73 49.3 0.008 0.874
Absent 268 130 48.5
Number of involved sites
One 185 73 39.5 0.167 0.001
Two or more 231 130 56.3
Liver metastasis
Present 154 97 63.0 0.218 o0.001
Absent 262 106 40.5
Lung metastasis
Present 114 54 47.4 0.018 0.721
Absent 302 149 49.3
Vertebral metastasis
Present 265 136 51.3 0.067 0.173
Absent 151 67 44.4
Skeletal-related events
Present 166 93 56.0 0.118 0.016
Absent 250 103 41.2
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Survival analysis for only bone metastasis
The mean PFS and OS for the 199 patients with only bony
involvement were 9.9 (1.0-75.5) and 24.4 (2.0-106.0) months,
respectively. The mean PFS and OS in patients with a normal
baseline S-ALP level were significantly longer than those
with an elevated S-ALP level (the mean PFS was 12.3 vs. 6.3
months, Po0.001; the median OS was 29.3 vs. 17.5 months,
Po0.001) (Figure 3A and 3B). The mean PFS and OS in
patients with a normal post-treatment S-ALP level were
significantly longer than in those with an elevated S-ALP
level (the mean PFS was 11.6 vs. 4.6 months, Po0.001;
the mean OS was 28.6 vs. 12.0 months, Po0.001) (Figure 3C
and 3D).
The 199 patients were divided into four subgroups
according to the pre-treatment S-ALP level and the post-
treatment S-ALP level: 1) elevated pre-treatment S-ALP
and elevated post-treatment S-ALP (34 patients); 2) elevated
pre-treatment S-ALP and normal post-treatment S-ALP
(48 patients); 3) normal pre-treatment S-ALP and elevated
post-treatment S-ALP (16 patients); 4) normal pre-treatment
S-ALP and normal post-treatment S-ALP (101 patients).
The mean PFS for these four subgroups was 4.0, 8.0, 6.1 and
13.3 months, respectively (Po0.001). The mean OS was 10.3,
22.5, 15.7 and 31.4 months, respectively (Po0.001) (Figure 3E
and 3F).
’ DISCUSSION
Among the distant metastatic sites from NPC, the skeleton
is one of the most common organs found to be involved (16).
Bone metastasis is a pathological status of bone metabolism
in which the normal balance between resorption of old bone
and formation of new bone is destroyed (17). Following up
changes in bone metabolism is crucial because it can provide
information for treatment evaluation in patients with skeletal
metastases. However, bone density changes occur too slowly
to allow the clinician to use an acceptable imaging test to
monitor the early response to treatment. X-ray has low
sensitivity and can only detect lesions when the diameters
of the bone metastatic sites are bigger than 1 cm. Bone
scans can detect bone lesions earlier than can X-ray, but
this method has low specificity and a high false-positive
rate. CT is radiative, PET/CT is expensive, and MRI also
suffers from limitations. It is therefore unpractical to use the
above means to dynamically monitor the changes in bone
metabolism.
In recent years, serum markers of bone formation and
resorption processes have held great promise as a new means
of obtaining the required information. Effective chemother-
apy for patients with skeletal metastatic NPC likely has a
favorable effect on serum biomarkers of bone turnover, but
this impact is still unknown (18–20). Alkaline phosphatase
(ALP) is a hydrolase enzyme responsible for removing
phosphate groups from many types of molecules, including
nucleotides, proteins, and alkaloids. The process of removing
the phosphate group is called dephosphorylation. In
humans, almost all tissues throughout the entire body
contain this enzyme, but it is particularly concentrated in
the bone, liver, bile duct, kidney, and placenta. Although
ALP is abundant in tissue cells, blood levels of the enzyme
are normally low. However, in some pathological and
specific physiological situations, they release more ALP into
the bloodstream. Conditions that can cause increased ALP in
the serum include pregnancy, bile duct obstruction, kidney
disease, hepatocellular carcinoma, and bone metastasis
(11,21-24).
Figure 1 - Correlation between the pre-treatment (and post-treatment) S-ALP level with the treatment responses of the 217 patients
who had measurable lesions. A) Pre-treatment S-ALP level and the treatment response are shown (chi-square test, P=0.217). B) Post-
treatment S-ALP level and the treatment response are shown (chi-square test, Po0.001).
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Figure 2 - Kaplan-Meier survival curves are shown for the total sample of 416 patients according to the pre-treatment (and post-
treatment) S-ALP level. A) PFS according to the pre-treatment S-ALP (Po0.001). B) OS according to the pre-treatment S-ALP (Po0.001).
C) PFS according to the post-treatment S-ALP (Po0.001). D) OS according to the post-treatment S-ALP (Po0.001). E) PFS according
to the combination of pre-treatment and post-treatment S-ALP (Po0.001). F) OS according to the combination of pre-treatment and
post-treatment S-ALP (Po0.001).
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An elevation of S-ALP is most frequently reported in bone
metastasis from certain malignancies, such as lung cancer,
breast cancer, and prostate cancer (25-27). Until now, the
clinical application of S-ALP in patients with skeletal
metastatic NPC has rarely been mentioned. This is the first
time the prognostic role and dynamic changes in the
significance of S-ALP in disseminated NPC with bone
involvement has been explored.
The results of this study are consistent with those several
of previous studies indicating that the activity of S-ALP is an
important prognostic factor for patients with bony malig-
nancies (28,29). In our report, elevated S-ALP levels were
significantly correlated with the presence of liver metastasis
and skeletal-related events, as well as the involvement of
more than one metastatic site. The median PFS and OS in
patients with a normal pre-treatment S-ALP level were
significantly longer than those with an elevated pre-
treatment S-ALP level. The same results were observed as
a correlation between the post-treatment S-ALP level and
survival outcome. Previous reports have also demonstrated
that elevated S-ALP levels are present in both primary and
metastatic liver tumors (30). Because the majority of S-ALP
consists of isoenzymes derived from liver and bone, it is
reasonable that patients with bony metastasis associated
with liver involvement have higher S-ALP levels than those
with only bone metastasis. The association between
increased pretreatment S-ALP activity and skeletal-related
events and the involvement of more than one metastatic site
also provide a rationale that the negative clinical prognosis
associated with elevated pretreatment S-ALP may simply be
attributed to a greater initial tumor burden and consequently
more advanced tumor stage.
As described above, practical imaging techniques for
evaluating the treatment response of bone metastases in a
timely manner are still lacking. Therefore, we have investi-
gated the predictive value of S-ALP and found that it could
serve as a marker to reflect the degree of regression or
progression during chemotherapy for the 217 patients who
also presented with measurable lesions (with lung or liver
metastasis). All 6 patients who achieved CR showed a
normal post-treatment S-ALP. Thirty-nine of the PR and 14 of
the SD patients showed a sharp drop in S-ALP from an
elevated level to a normal level. The response rate was
significantly higher in patients with a normal post-treatment
S-ALP level compared with those with a sustained high post-
treatment S-ALP level. S-ALP levels have been demonstrated
to reflect the growth and regression of various malignant
neoplasms. Guru Sonpavde et al evaluated the association
between changes in the S-ALP within 90 days with OS in
men with castration-resistant prostate cancer and bone
metastases treated with docetaxel or mitoxantrone in the
TAX327 trial. The results showed that the normalization of
S-ALP by day 90 predicted better survival and that an
increase in S-ALP by day 90 predicted poor survival (11).
Maisano R et al reported that in 103 consecutive patients
with metastatic colorectal cancer treated with chemotherapy,
only 3 patients in the high alkaline phosphatase group
obtained a partial response (9.4%) compared to 3 complete
Table 2 - Univariate and multivariate analysis of progression-free survival.
Factors Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value HR (95% CI)
Sex: Male or female 0.345 0.871 (0.654-1.160)
Age: o45 years or Z45 years 0.904 0.988 (0.808-1.208)
Metastasis at presentation: Present or absent 0.023 1.284 (1.035-1.594)
Liver metastasis: Present or absent 0.122 1.284 (0.936-1.760)
Lung metastasis: Present or absent 0.060 1.336 (0.987-1.808)
Pre-treatment S-ALP level: Normal or elevated o0.001 1.602 (1.294-1.985) o0.001 1.656 (1.345-2.040)
Post-treatment S-ALP level: Normal or elevated o0.001 2.254 (1.784-2.848) o0.001 2.226 (1.780-2.783)
Number of drugs for chemotherapy:Two or three 0.047 0.802 (0.645-0.997)
Number of involved sites: 1 or Z1 0.704 0.928 (0.629-1.367)
Vertebral metastasis: Present or absent 0.984 1.002 (0.816-1.231)
Skeletal-related events: Present or absent 0.899 0.980 (0.723-1.329)
HR: hazard ratio; 95% CI: 95% confidence interval.
Table 3 - Univariate and multivariate analysis of overall survival.
Factors Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value HR (95% CI)
Sex: Male or female 0.256 0.845 (0.632-1.130)
Age: o45 years or Z45 years 0.385 1.094 (0.894-1.338)
Metastasis at presentation: Present or absent 0.523 1.074 (0.862-1.338)
Liver metastasis: Present or absent 0.995 1.001 (0.736-1.361)
Lung metastasis: Present or absent 0.894 0.980 (0.724-1.325)
Pre-treatment S-ALP level: Normal or elevated o0.001 1.794 (1.453-2.214) o0.001 1.794 (1.462-2.201)
Post-treatment S-ALP level: Normal or elevated o0.001 2.777 (2.195-3.514) o0.001 2.657 (2.122-3.327)
Number of drugs for chemotherapy: Two or three 0.881 1.017 (0.820-1.261)
Number of involved sites: 1 or Z1 0.811 0.954 (0.645-1.409)
Vertebral metastasis: Present or absent 0.069 1.210 (0.985-1.486)
Skeletal-related events: Present or absent 0.657 0.933 (0.688-1.265)
HR: hazard ratio; 95% CI: 95% confidence interval.
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Figure 3 - Kaplan-Meier survival curves are shown for the 199 patients with only bony involvement according to the pre-treatment
(and post-treatment) S-ALP level. A) PFS according to the pre-treatment S-ALP (Po0.001). B) OS according to the pre-treatment S-ALP
(Po0.001). C) PFS according to the post-treatment S-ALP (Po0.001). D) OS according to the post-treatment S-ALP (Po0.001). E) PFS
according to the combination of pre-treatment and post-treatment S-ALP (Po0.001). F) OS according to the combination of
pre-treatment and post-treatment S-ALP (Po0.001).
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responses and 24 partial responses (41.5%) in the low
alkaline phosphatase group (31).
The Cox proportional hazard regression model revealed
that only the pre-treatment S-ALP level and post-treatment
S-ALP level were independent prognostic factors for overall
survival. Notably, when both the pre-treatment and post-
treatment S-ALP were considered during analysis, SREs and
vertebral involvement were no longer found to be indepen-
dent negative factors, as described in our previous research
(7). As we reported previously (14), one reasonable explana-
tion is that serum tumor markers can reflect the tumor burden
more sensitively and precisely than can the specific site of
metastases. Additionally, the various sizes and quantities of
the lesions may have different prognostic implications.
Numerous large lesions may represent a more extensive
spread than that of fewer small lesions. These findings
provide a rationale for why S-ALP levels have stood out as
an independent prognostic factor for survival outcome.
After confirming the prognostic role of S-ALP, we further
separated the patients into four subgroups according to their
survival outcomes by analyzing the pre-treatment and post-
treatment S-ALP in combination. The results revealed that
the combination of pre-treatment and post-treatment S-ALP
was able to discriminate patients with good prognosis from
those with poor prognosis in bony metastatic NPC with or
without visceral involvement.
There are several limitations in this study. First, because it
is a retrospective study, the patients may have had other
nonspecific causes of S-ALP elevation. Second, S-ALP is not
fractionated to a specific phenotype in the routine test in our
center, and therefore, a bone-specific alkaline phosphatase is
not available. However, the inclusion criteria of this study
required patients with normal renal, cardiac and liver
function; hence, it is unlikely that hepatic dysfunction or
renal disease is a significant confounding cause of the
observed elevations in S-ALP. Another caveat is that the
normal ranges of S-ALP differ slightly in different labora-
tories. We choose a conventionally accepted normal range for
ALP of 110 IU/L in this study.
In conclusion, S-ALP appears to be a useful marker to
predict survival and monitor the response to treatment for
bony metastatic NPC. Given that the measurement of S-ALP
is a simple, readily quantifiable, inexpensive, and established
routine diagnostic test that is easily available with quick
results, further prospective research on the usefulness of
S-ALP determination for the monitoring of bone metastases
is certainly worthwhile.
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